Lung Pathology Detection
Lung Pathology Detection - Related Videos
05:15
Noninvasive Intratracheal Intubation to Study the Pathology and Physiology of Mouse Lung
0 Views •
Cited by 22 •
2013
The use of a model that mimics the condition of lung diseases in humans is critical for studying the pathophysiology and/or etiology of a particular disease and for developing therapeutic intervention. Here a noninvasive intratracheal intubation method that can directly deliver exogenous materials to mouse lungs is presented.
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
08:54
Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
0 Views •
Cited by 19 •
2020
Intravenous injection of cancer cells is often used in metastasis research, but the metastatic tumor burden can be difficult to analyze. Herein, we demonstrate a tail-vein injection model of metastasis and include a novel approach to analyze the resulting metastatic lung tumor burden.
05:35
Lung Instillation and Fixation: Introducing Liquid into the Trachea and Fixing Lungs to Measure the Fixed Lung Volume
0 Views •
2023
This video describes a simple and reliable method of introducing liquid into the trachea for lung instillation, fixation, and lung volume measurement.
09:49
Measurement of the Pressure-volume Curve in Mouse Lungs
0 Views •
Cited by 47 •
2015
Here we present a protocol to simply and reliably measure the lung pressure-volume curve in mice, showing that it is sufficiently sensitive to detect phenotypic parenchymal changes in two common lung pathologies, pulmonary fibrosis and emphysema. This metric provides a means to quantify the lung’s structural changes with developing pathology.
FAQs
Each approach contributes a different level of evidence. Clinical assessment frames the respiratory problem, imaging shows structural distribution and disease extent, bronchoscopy permits direct airway evaluation and sampling, and microscopy characterizes tissue or cellular changes. Combining these findings helps clinicians connect visible abnormalities with their underlying pathology instead of relying on a single observation.
Specialized stains can highlight pathogens or particular tissue features that may be difficult to recognize in routine microscopic examination. Molecular tests add another layer by detecting disease-associated biomarkers or pathogen-related material. Together, these methods can strengthen characterization of an abnormality, support distinction between similar disorders, and provide information relevant to treatment selection.
Different lung disorders can produce overlapping respiratory findings, so the pattern of tissue injury and cellular change becomes important. Microscopic examination can reveal abnormal cell features, inflammatory changes, fibrosis, or evidence of infection, while imaging contributes structural context. Interpreting both dimensions helps clarify disease type, extent, and severity, which supports more precise clinical assessment.
The workflow begins with clinical assessment and imaging to identify and characterize a suspected abnormality. When additional evidence is needed, bronchoscopy may support direct evaluation and specimen collection, followed by tissue examination under a microscope. Specialized stains or molecular testing can then investigate pathogens, abnormal features, or biomarkers, allowing the combined findings to inform diagnosis and management.
Tissue sampling adds value when structural findings alone do not adequately characterize a pulmonary abnormality. Bronchoscopy and biopsy provide material for microscopic examination, allowing investigators to assess cellular changes and tissue patterns directly. Additional staining or molecular analysis may further clarify infection, inflammation, fibrosis, or cancer-related findings, helping distinguish conditions with similar imaging appearances.
Findings from lung pathology detection can guide treatment selection by identifying disease characteristics, pathogens, or disease-associated biomarkers. They also help establish disease extent and severity, which contributes to prognosis. Repeated assessment can support monitoring of therapeutic response, while research applications use structural, cellular, and molecular findings to investigate mechanisms underlying pulmonary disease.